FOSTER CITY, CA--(Marketwire - Jan 7, 2013) - SciClone

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
FOSTER CITY, CA--(Marketwire - Jan 7, 2013) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced its anticipated 2013 initial revenue, earnings per share (EPS) and year-end cash guidance, and 2012 year-end cash position, as follows: The Company anticipates 2013 sales revenue of $150 million - $155 million. The Company expects 2013 non-GAAP EPS of $0.66 - $0.72 per share. SciClone's non-GAAP EPS excludes employee stock-based compensation from GAAP EPS. The Company anticipates 2013 year-end cash and investments balances to be greater than $105 million excluding any impacts on cash balances associated with the Company's acquisition of new products, ongoing stock repurchase program and any other unbudgeted one-time cash expenses. The Company expects cash and investments balances to be approximately $87 million (unaudited) at December 31, 2012. Excluding the cash impact of fourth quarter 2012 repurchases of common stock from the Company's share repurchase program, cash and investments would have been approximately $93 million (unaudited). Excluding the cash impact of the full-year 2012 repurchases of common stock from the Company's share repurchase program, cash and investments would have been approximately $112 million (unaudited). "During the second half of 2012, we took important steps to strengthen our on-going business and improve our future financial performance, including recruiting high level executives with multinational pharmaceutical management experience into the China organization and significantly enhancing our sales and marketing strategies to increase demand and expand market penetration and growth for ZADAXIN® and our other products," commented Friedhelm Blobel, Ph.D., President and Chief Executive Officer. "We believe that implementation of these strategies will begin to positively affect sales growth over the next several quarters, and position SciClone to regain growth momentum as 2013 progresses." SciClone expects to report its complete fourth quarter and full-year 2012 financial results in early March 2013. About SciClone SciClone Pharmaceuticals is a US-based, China-focused specialty pharmaceutical company with a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. SciClone's ZADAXIN® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. Besides ZADAXIN, SciClone markets about 14 mostly partnered products in China, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China; Tritace®, an ACE inhibitor for the treatment of hypertension; Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US); and Aggrastat®, a recently-launched interventional cardiology product. SciClone is also pursuing the registration of several other therapeutic products in China. SciClone is headquartered in Foster City, California. For additional information, please visit www.sciclone.com. Forward-Looking Statements This press release contains forward-looking statements regarding expected financial results and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These include risks and uncertainties relating to: changes in results that may occur in completing the close of SciClone's consolidated financial statements for fiscal year 2012 and completing the audit of SciClone's consolidated financial statements for fiscal year 2012; the course, cost and outcome of regulatory matters; the Company's ability to execute on its goals in China and on its objectives for revenue in fiscal 2013; the challenges presented by integrating an acquired business into existing operations; the variability in earnings on a GAAP basis that may result from non-cash charges related to the NovaMed acquisition; the dependence on third-party license, promotion or distribution agreements including the need to renew such agreements; operating an international business; the clinical trial process, including the regulatory approval and the process of initiating trials at, and enrolling patients at, clinical sites; the effect of changes in its practices and policies related to the Company's compliance programs and SciClone's ability to attract and retain key personnel. SciClone cannot predict the timing or outcome of the SEC and DOJ investigations, or of the level of its efforts required to cooperate with those investigations, however the Company has incurred substantial expenses in connection with the investigations and related litigation and expects to incur additional expense and the investigations could result in fines and further changes in its internal control or other remediation measures that could adversely affect its business. Please also refer to other risks and uncertainties described in SciClone's filings with the SEC. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements. Ambien, Depakine, Stilnox and Tritace are registered trademarks of Sanofi and/or its affiliates. Aggrastat is a registered trademark of Medicure International Inc. in the United States, and Iroko Cardio LLC in numerous other countries. SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals design, the SciClone logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries. Corporate Contacts Gary Titus Chief Financial Officer 650.358.3456gtitus@sciclone.com Jane Green Investors/Media 650.358.1447jgreen@sciclone.com

View More
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mall of America Strives for World Record This Black Friday

Updated Category News Views 67

History in the Making at Mall of America Yeah, it seems these folks are not just about shopping anymore. The Mall of America is aiming to set the bar high this Black Friday, eyeing a GUINNESS WORLD RECORDS title for the most people holding up the same shopping bag all at once. Imagine a thousand people, synchronized like a flash mob—only with shopping bags instead of...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 87

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 49

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 182

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 108

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Radiotherapy Suit Challenges New EviCore Guidelines

Updated Category News Views 63

Turning Up the Heat on EviCore Winter Park, Florida—home of sunshine, oranges, and now a heated legal standoff. On November 16, 2026, the Radiotherapy Access Alliance dropped a bombshell lawsuit against EviCore over its recent guideline flip-flop. EviCore reversed its stance on low-dose radiation therapy (LDRT) for arthritis and other pesky pain, leaving patients—and...

Continue Reading
Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 32

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
Parallels Desktop Tops 2026 Picks for Windows on Mac

Updated Category News Views 41

Diving into the Cross-Platform Conundrum Now, I've been in the trenches long enough to know that when companies start relying on Mac computers but can't ditch their essential Windows apps, they're bound to hit a digital brick wall. Picture this—accounting, enterprise management, all that jazz that still needs Windows to function. For those jumping between these two...

Continue Reading
Tammy Keller's Devotional Guides Living with Purpose

Updated Category News Views 77

Finding Meaning in the Dash of Life Life isn’t just bookended by birth and death; it’s the dash in between that counts. If you were sitting next to Tammy Keller right now, you’d probably hear that heartfelt truth straight from her. Her new work, "Your--Dash Devotional," rattles the soul by offering a profound look at making every moment intentional, vivid, and...

Continue Reading
CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 111

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading

Top 5 Most Recently Viewed Articles

Ray Dalio Warns of Economic Heart Attack and Gold Investment

Updated Category News Views 330

Debt-Fueled Risks in the U.S. Economy Ray Dalio, founder of Bridgewater Associates, has recently shared his concerns regarding the growing debt burden facing the U.S. economy. According to Dalio, this financial strain resembles arterial blockage, leading to the possibility of a severe economic "heart attack." His warning speaks volumes as the national debt continues to...

Continue Reading
Citi Projects Stronger Global Economic Growth in 2024

Updated Category News Views 249

Global Economic Outlook for 2024 In a recent report, Citi's group of economists has expressed optimism about the global economic scene for 2024. They predict that the economy will exceed earlier expectations, thanks in part to lower interest rates and positive trends emerging from several markets. These elements create a more encouraging environment for growth compared to...

Continue Reading
Quarterhill Welcomes David Charron as CFO to Drive Growth

Updated Category News Views 226

David Charron Takes the Helm as Quarterhill's CFO Quarterhill Inc. (TSX: QTRH) is excited to announce that David Charron has been appointed as the new Chief Financial Officer (CFO). This strategic move comes as the company gears up for its next phase of growth. David brings over 15 years of experience in leadership roles within public technology companies, making him a...

Continue Reading
Autolus Therapeutics: Key Insights Ahead of Earnings Release

Updated Category News Views 209

Overview of Autolus Therapeutics Earnings Report Autolus Therapeutics (NASDAQ: AUTL) is preparing to share its quarterly earnings results soon. Investors are keenly anticipating this announcement, which will give them a clearer picture of the company’s performance and future direction. Forecasts and Market Expectations Analysts are projecting a loss per share (EPS) of...

Continue Reading
Blue Diamond Growers Earns Star Site Award for Safety Excellence

Updated Category News Views 299

Blue Diamond Growers Achieves Recognition for Safety Standards Blue Diamond Growers, the leading cooperative in almond marketing and processing, has reached a significant milestone by receiving the "Star Site" designation from Cal/OSHA. This recognition is awarded to employers who have excelled in managing safety and health programs effectively. Exceptional Safety at the...

Continue Reading